

Abbreviations

ADC	antibody-drug conjugate	MSI	microsatellite instability
AEs	adverse events	mut/Mb	mutations per million bases
ASCO	American Society of Clinical Oncology	NCCN	National Comprehensive Cancer Network
CC	cervical cancer	NK	natural killer
CCRT	concurrent chemoradiotherapy	NMPA	China National Medical Products Administration
CPS	combined positive score	ORR	objective response rate
CRs	complete responses	OS	overall survival
CTLA-4	cytotoxic T-lymphocyte-associated protein 4	PD-1	programmed cell death-1
DCR	disease control rate	PD-L1	programmed cell death ligand-1
DCs	dendritic cells	PFS	progression-free survival
DLTs	dose-limiting toxicities	PRs	partial responses
DMFS	distance metastasis-free survival	R/M	recurrent/metastatic
DOR	duration of response	SCC	squamous cell carcinoma
FDA	U.S. Food and Drug Administration	SDs	stable disease
FIGO	International Federation of Gynecology and Obstetrics	SGO	Society for Gynecologic Oncology
HPV	human papillomavirus	TGF-βRII	transforming growth factor- β receptor II
hrHPVs	high-risk HPV subtypes	TIGIT	T cell immunoglobulin and ITIM domains
ICB	immune checkpoint blockade	TILs	tumor-infiltrating lymphocytes
ICOS	inducible T-cell costimulator	TMB	tumor mutational burden
IDO1	indoleamine 2, 3-dioxygenase 1	TME	tumor microenvironment
irAE	immune-related adverse events	TRAEs	treatment-related adverse events
LACC	locally advanced cervical cancer	TV	Tisotumab vedotin
mAb	monoclonal antibody	VEGFR-2	vascular endothelial growth factor receptor-2